This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Dantrolene in the treatment of spasticity

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • dantrolene sodium - inhibits the release of calcium from the sarcoplasmic reticulum and thus causing a dissociation of excitation-contraction coupling. The main side effect is hepatotoxicity

  • evidence from double-blind comparative studies suggest that the efficacy of dantrolene is comparable to that of baclofen and diazepam (1,2)

Reference:

  • (1) Ward A, Chaffman MO, Sorkin EM (1986). Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs, 32, 130-68.
  • (2) Schmidt RT, Lee RH, Spehlmann R (1976). Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurosurg Psychiatry, 39, 350-6.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.